52-Week Performance Chart

Powered by FactSet Research Systems Inc

Recent Company News

More

Corporate Actions/Books Closed

No DR Events are available.

Data provided by Thomson Reuters

Recent Dividends & Distributions

More
US RECORD DATE US PAYABLE DATE NET DR AMOUNT
Mar 31, 2025 TBA TBA
Sep 30, 2024 Dec 16, 2024 0.0792
Mar 28, 2024 Jul 11, 2024 0.0825
Sep 29, 2023 Dec 15, 2023 0.0839

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
Advisors Capital Management LLC 3,200
Copeland Capital Management LLC 230
RhumbLine Advisers LP 30
TOP MUTUAL FUND HOLDERS POSITION
Advisors Capital International Fund 3,200

Data provided by FactSet Research Systems Inc.

Important Notice to Investors of Unsponsored DRs and GDNs:

From time to time, BNY may pay a rebate to brokers that deposit shares with BNY for the issuance of unsponsored depositary receipts (DRs) or global depositary notes. BNY assumes no obligation or responsibility, and expressly disclaims any liability arising out of, or relating to, such rebates, including without limitation whether the rebate or any portion of it is passed on to the beneficial holders by the brokers.
Unsponsored DRs may be issued by multiple depositary banks servicing a particular DR program. Consequently, as a result of Depository Trust & Clearing Corporation (“DTCC”) practice, the actual cash distribution fees charged may differ from the BNY fees detailed in the fee schedule as fees will be charged in accordance with the fee schedule of the depositary bank that is considered to be the “First Filer”. The fees to be charged for any particular unsponsored cash distribution will be disclosed on the event announcement published by the “First Filer”. BNY takes no responsibility for the level of fees charged by any other depositary bank. The “First Filer” is the depositary bank that filed the first Form F-6 for a program with the U.S. Securities and Exchange Commission (“SEC”). In the event the actual “First Filer” does not have DRs outstanding for a program, the next depositary bank who filed a
Form F-6 with the SEC and has DRs outstanding will be deemed to be the First Filer for these purposes.

DR Details

DR Symbol SNPHY
CUSIP 80287P100
DR Venue OTC
DR ISIN US80287P1003
Ratio DR:ORD 1:1
First Filer BK
Underlying ISIN JP3336000009
Underlying SEDOL 6776606
Country Japan
Effective Date Sep 10, 2010
Depositary BK, CIT, DB, JPMC (Unsponsored)
Industry Pharma. & Biotech.
Santen Pharmaceutical is a pharmaceutical company mainly engaged in the research and development, production and marketing of pharmaceuticals and medical devices. The Company operates its business in Japan, Asia, North America, Europe, Middle East and Africa, and sells its products in over 50 countries. The Company offers prescription ophthalmic pharmaceutical products such as treatments for corneal and conjunctival epithelial disorders, glaucoma, anti-infective ophthalmics and anti-allergy ophthalmics. The Company also officers over-the-counter (OTC) pharmaceuticals such as eye drops. In addition, the Company provides ophthalmic medical devices used in cataract surgery, and cleaning services for sterilized clothes.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.1000
Cancellation up to $0.1000
Cash Distribution up to $0.1000
Issuance up to $0.1000
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.1000
Rights - Issuance up to $0.1000
Stock Dividend up to $0.1000
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 10.29 180,620 8,601
Mar.25 9.47 100,254 4,774
Feb.25 9.26 132,182 6,957

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE